Sovaldi price worries states

Share this article:

Gilead's hepatitis C drug Sovaldi is giving Medicaid and private insurers a headache. Reuters reports that several insurers are talking with state agencies about how to handle Medicaid payments for a treatment that costs around $84,000 per person.

Reuters notes that this can also be just a starting price and that “many doctors are requesting a $150,000 combination of Sovaldi (sofosbuvir) and Olysio (simeprevir).”

This too, is a starting point of sorts: Harvard Medical School's Camilla Graham told Reuters that a cumulative number would probably hover around the $200 billion mark to treat two-thirds of hepatitis C patients at around $100,000 each.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.